Abstract: Ovarian cancer is one of the major health- and life-threatening diseases among females. In recent years, poly (ADP-ribose) polymerase inhibitors (PARPi), as novel molecular-targeted therapy agents that bring benefits to ovarian cancer patients, have been recommended as maintenance therapy for platinum-sensitive recurrent ovarian cancer patients and postoperative maintenance therapy by several clinical guidelines. However, the safety issues, especially the hematological toxicities of the drugs, should be carefully regarded. This review compared the pharmacological characteristics and hematological toxicities of three different PARPi, so as to provide more information of the clinical application for the recurrent ovarian cancer patients.

Key words: Platinum-sensitive recurrence, Ovarian cancer, Poly (ADP-ribose) polymerase inhibitors, Hematological toxicity